Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-08

AUTHORS

C. Michael Gibson, Cafer Zorkun, Peter Molhoek, Krzysztof Żmudka, Mark Greenberg, Hiltrud Mueller, Jan Wesdorp, Hans Louwerenburg, Alan Niederman, Jaap Westenburg, Mahesh Bikkina, John Batty, Jobst de Winter, Sabina A. Murphy, Carolyn H. McCabe

ABSTRACT

BACKGROUND: Currently available fibrinolytic agents are limited by their ability to restore normal blood flow in only half of patients, the risk of reocclusion, and the risk of intracranial hemorrhage. The genetically engineered agent BB-10153 is activated by thrombin, not plasminogen activator enzymes, which limits its activity to the site of thrombus which may in turn reduce the risk of systemic bleeding. BB-10153 also has a relatively long half-life of 3-4 hours, which may also limit the potential for early reocclusion [1, 2]. METHODS: The study was a phase II, open-label, multi-center, dose escalation, single-dose administration study to determine the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of BB-10153 in ST segment elevation MI (STEMI). STEMI patients (n = 50) received a single dose of BB-10153 at one of six dose levels (1.0, 2.0, 3.0, 5.0, 7.5 and 10 mg/kg). The primary endpoint was TIMI flow grade (TFG) 3 at 60 minutes following the intravenous bolus of BB-10153. RESULTS: Mean area under the curve for drug concentration ranged from 48.0 microg.h/mL in the 1 mg/kg dose group to 788.6 microg.h/mL in the 10 mg/kg dose group. Likewise, mean Cmax generally increased with dose over the entire dose range, from 4.9 microg/mL in the 1 mg/kg dose group to 139.6 microg/mL in the 10 mg/kg dose group. The mean apparent terminal half-life (t1/2) was 4.4 hours (range 2.2 to 7.6 hours). Few patients in the 1-3 mg/kg dosage groups achieved TFG 3 on the one-hour post-dose angiogram (4/20, 20%), and no patients achieved complete ST segment resolution. The 5, 7.5 and 10 mg/kg doses were associated with similar rates of TIMI grade 3 flow of approximately three per seven patients. Pooling TFG 3 data from the 5, 7.5 and 10 mg/kg groups yielded a TIMI grade 3 flow rate of 34% (n = 10/29; range 29-43%). No patients experienced 30-day death, recurrent acute MI, cardiogenic shock, stroke or anaphylaxis during the study. One patient experienced recurrent angina and developed recurrent myocardial ischemia requiring urgent revascularization. Three patients sustained TIMI major bleeding events (one in 1 mg/kg group, two in 7.5 mg/kg group), six patients sustained TIMI minor bleeds (one in the 2, 3, 7.5 and 10 mg/kg groups, two in the 5 mg/kg group), twp patients sustained TIMI minimal bleeds (one in each of the 2 and 10 mg/kg groups) and no patients sustained intracranial hemorrhage (ICH). CONCLUSION: In a dose escalation study of a single intravenous bolus, the novel fibrinolytic agent, BB-10153 was associated with a rise in the mean area under the curve and Cmax for drug concentration over the dose range 1 to 10 mg/kg. Higher doses were associated with a range of TIMI grade 3 flow of 29-43%, and no patients experienced 30-day death, recurrent acute MI, cardiogenic shock, stroke or anaphylaxis during the study. In a dose escalation study of a single intravenous bolus, the novel fibrinolytic agent, BB-10153 was associated with a rise in the mean area under the curve and Cmax for drug concentration over the dose range 1 to 10 mg/kg. Higher doses were associated with a range of TIMI grade 3 flow of 29-43%, and no patients experienced 30-day death, recurrent acute MI, cardiogenic shock, stroke or anaphylaxis during the study. More... »

PAGES

13-21

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11239-006-8080-1

DOI

http://dx.doi.org/10.1007/s11239-006-8080-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1041620834

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16786228


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Coronary Angiography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fibrinolytic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Injections, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myocardial Infarction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Myocardial Reperfusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Plasminogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Regional Blood Flow", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thrombolytic Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Harvard University", 
          "id": "https://www.grid.ac/institutes/grid.38142.3c", 
          "name": [
            "TIMI Study Group, Cardiovascular Division, Brigham & Women\u2019s Hospital and the Department of Medicine, Harvard Medical School, 350 Longwood Avenue, First Floor, 02115, Boston, MA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gibson", 
        "givenName": "C. Michael", 
        "id": "sg:person.0750215673.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750215673.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "John Paul II Hospital", 
          "id": "https://www.grid.ac/institutes/grid.414734.1", 
          "name": [
            "John Paul II Hospital, Krakow, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zorkun", 
        "givenName": "Cafer", 
        "id": "sg:person.01100507210.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100507210.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medisch Spectrum Twente", 
          "id": "https://www.grid.ac/institutes/grid.415214.7", 
          "name": [
            "Medisch Spectrum Twente, Enschede, Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Molhoek", 
        "givenName": "Peter", 
        "id": "sg:person.01351654467.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351654467.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "John Paul II Hospital", 
          "id": "https://www.grid.ac/institutes/grid.414734.1", 
          "name": [
            "John Paul II Hospital, Krakow, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "\u017bmudka", 
        "givenName": "Krzysztof", 
        "id": "sg:person.0654626714.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654626714.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Montefiore Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.240283.f", 
          "name": [
            "Montefiore Medical Center, New York, New York"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Greenberg", 
        "givenName": "Mark", 
        "id": "sg:person.0576424350.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576424350.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Montefiore Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.240283.f", 
          "name": [
            "Montefiore Medical Center, New York, New York"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mueller", 
        "givenName": "Hiltrud", 
        "id": "sg:person.01116742633.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116742633.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Spaarne Ziekenhuis", 
          "id": "https://www.grid.ac/institutes/grid.416219.9", 
          "name": [
            "Spaarne Ziekenhuis, Heemstede, Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wesdorp", 
        "givenName": "Jan", 
        "id": "sg:person.01343671735.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343671735.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medisch Spectrum Twente", 
          "id": "https://www.grid.ac/institutes/grid.415214.7", 
          "name": [
            "Medisch Spectrum Twente, Enschede, Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Louwerenburg", 
        "givenName": "Hans", 
        "id": "sg:person.01203545141.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203545141.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "North Ridge Medical Center, Fort Lauderdale, Florida"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Niederman", 
        "givenName": "Alan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Scheperziekenhuis, Emmen, Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Westenburg", 
        "givenName": "Jaap", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "St Josephs Medical Center, Paterson, New Jersey"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bikkina", 
        "givenName": "Mahesh", 
        "id": "sg:person.0667527074.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667527074.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "New Mexico Heart Institute", 
          "id": "https://www.grid.ac/institutes/grid.489081.c", 
          "name": [
            "New Mexico Heart Institute, Albuquerque, New Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Batty", 
        "givenName": "John", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Cardioloog, Tweesteden Ziekenhuis, Tilberg, Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Winter", 
        "givenName": "Jobst", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Harvard University", 
          "id": "https://www.grid.ac/institutes/grid.38142.3c", 
          "name": [
            "TIMI Study Group, Cardiovascular Division, Brigham & Women\u2019s Hospital and the Department of Medicine, Harvard Medical School, 350 Longwood Avenue, First Floor, 02115, Boston, MA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Murphy", 
        "givenName": "Sabina A.", 
        "id": "sg:person.0714034144.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714034144.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Harvard University", 
          "id": "https://www.grid.ac/institutes/grid.38142.3c", 
          "name": [
            "TIMI Study Group, Cardiovascular Division, Brigham & Women\u2019s Hospital and the Department of Medicine, Harvard Medical School, 350 Longwood Avenue, First Floor, 02115, Boston, MA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McCabe", 
        "givenName": "Carolyn H.", 
        "id": "sg:person.0647744174.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647744174.31"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1161/01.cir.0000013402.34759.46", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005846812"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1538-7836.2004.01087.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013221463"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1538-7836.2005.01352.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035738711"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1538-7836.2005.01352.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035738711"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0735-1097(03)00123-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037948616"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0735-1097(03)00123-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037948616"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198504043121437", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040546057"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.101.2.125", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043155754"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.99.21.2720", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045038090"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.93.5.879", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063337016"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.7326/0003-4819-115-4-256", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073695908"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082701238", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-08", 
    "datePublishedReg": "2006-08-01", 
    "description": "BACKGROUND: Currently available fibrinolytic agents are limited by their ability to restore normal blood flow in only half of patients, the risk of reocclusion, and the risk of intracranial hemorrhage. The genetically engineered agent BB-10153 is activated by thrombin, not plasminogen activator enzymes, which limits its activity to the site of thrombus which may in turn reduce the risk of systemic bleeding. BB-10153 also has a relatively long half-life of 3-4 hours, which may also limit the potential for early reocclusion [1, 2].\nMETHODS: The study was a phase II, open-label, multi-center, dose escalation, single-dose administration study to determine the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of BB-10153 in ST segment elevation MI (STEMI). STEMI patients (n = 50) received a single dose of BB-10153 at one of six dose levels (1.0, 2.0, 3.0, 5.0, 7.5 and 10 mg/kg). The primary endpoint was TIMI flow grade (TFG) 3 at 60 minutes following the intravenous bolus of BB-10153.\nRESULTS: Mean area under the curve for drug concentration ranged from 48.0 microg.h/mL in the 1 mg/kg dose group to 788.6 microg.h/mL in the 10 mg/kg dose group. Likewise, mean Cmax generally increased with dose over the entire dose range, from 4.9 microg/mL in the 1 mg/kg dose group to 139.6 microg/mL in the 10 mg/kg dose group. The mean apparent terminal half-life (t1/2) was 4.4 hours (range 2.2 to 7.6 hours). Few patients in the 1-3 mg/kg dosage groups achieved TFG 3 on the one-hour post-dose angiogram (4/20, 20%), and no patients achieved complete ST segment resolution. The 5, 7.5 and 10 mg/kg doses were associated with similar rates of TIMI grade 3 flow of approximately three per seven patients. Pooling TFG 3 data from the 5, 7.5 and 10 mg/kg groups yielded a TIMI grade 3 flow rate of 34% (n = 10/29; range 29-43%). No patients experienced 30-day death, recurrent acute MI, cardiogenic shock, stroke or anaphylaxis during the study. One patient experienced recurrent angina and developed recurrent myocardial ischemia requiring urgent revascularization. Three patients sustained TIMI major bleeding events (one in 1 mg/kg group, two in 7.5 mg/kg group), six patients sustained TIMI minor bleeds (one in the 2, 3, 7.5 and 10 mg/kg groups, two in the 5 mg/kg group), twp patients sustained TIMI minimal bleeds (one in each of the 2 and 10 mg/kg groups) and no patients sustained intracranial hemorrhage (ICH).\nCONCLUSION: In a dose escalation study of a single intravenous bolus, the novel fibrinolytic agent, BB-10153 was associated with a rise in the mean area under the curve and Cmax for drug concentration over the dose range 1 to 10 mg/kg. Higher doses were associated with a range of TIMI grade 3 flow of 29-43%, and no patients experienced 30-day death, recurrent acute MI, cardiogenic shock, stroke or anaphylaxis during the study. In a dose escalation study of a single intravenous bolus, the novel fibrinolytic agent, BB-10153 was associated with a rise in the mean area under the curve and Cmax for drug concentration over the dose range 1 to 10 mg/kg. Higher doses were associated with a range of TIMI grade 3 flow of 29-43%, and no patients experienced 30-day death, recurrent acute MI, cardiogenic shock, stroke or anaphylaxis during the study.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11239-006-8080-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1113719", 
        "issn": [
          "0929-5305", 
          "1573-742X"
        ], 
        "name": "Journal of Thrombosis and Thrombolysis", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "22"
      }
    ], 
    "name": "Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial", 
    "pagination": "13-21", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c6443e856a7542c8b540ecda11ecee3e91ead9794cc1006c9641323ede610c1d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16786228"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9502018"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11239-006-8080-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1041620834"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11239-006-8080-1", 
      "https://app.dimensions.ai/details/publication/pub.1041620834"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T02:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000523.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs11239-006-8080-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11239-006-8080-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11239-006-8080-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11239-006-8080-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11239-006-8080-1'


 

This table displays all metadata directly associated to this object as RDF triples.

275 TRIPLES      21 PREDICATES      54 URIs      36 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11239-006-8080-1 schema:about N0516ebd38c464f0dbe7bbe577094b479
2 N0a6720f8b3df484bbf031f72b6fbb583
3 N13d1bc8932214f42a3afc90b2f49b38e
4 N2e66a741227c40f2ad69187269ba5845
5 N4ac9839457394f9bb9d84c94cc0d0c37
6 N6a34647481ab41bb829d6357e66edb72
7 N73fc0e7deb844926b0bf5848b8c2ebe2
8 N79927ac060bd49abbb4e147f9d9dd912
9 N8331831fbd1d4eeb8ef45f87cc08c3be
10 N911ebf7cbef84341910adb87f83df6a9
11 N9562184b5b1b4780a7c186b275954d8b
12 N98b8ed5dccbe4239a7942dc9c8995bca
13 Nac81ac8731944e01a1859c3046ee187d
14 Nc46764fc33cd4c3f82aac186a551cd8c
15 Nc75b1616e42f4b66b7b4778c16974e97
16 anzsrc-for:11
17 anzsrc-for:1117
18 schema:author Ncd1455d8233049518d75c93a5bd534ab
19 schema:citation https://app.dimensions.ai/details/publication/pub.1082701238
20 https://doi.org/10.1016/s0735-1097(03)00123-2
21 https://doi.org/10.1056/nejm198504043121437
22 https://doi.org/10.1111/j.1538-7836.2004.01087.x
23 https://doi.org/10.1111/j.1538-7836.2005.01352.x
24 https://doi.org/10.1161/01.cir.0000013402.34759.46
25 https://doi.org/10.1161/01.cir.101.2.125
26 https://doi.org/10.1161/01.cir.93.5.879
27 https://doi.org/10.1161/01.cir.99.21.2720
28 https://doi.org/10.7326/0003-4819-115-4-256
29 schema:datePublished 2006-08
30 schema:datePublishedReg 2006-08-01
31 schema:description BACKGROUND: Currently available fibrinolytic agents are limited by their ability to restore normal blood flow in only half of patients, the risk of reocclusion, and the risk of intracranial hemorrhage. The genetically engineered agent BB-10153 is activated by thrombin, not plasminogen activator enzymes, which limits its activity to the site of thrombus which may in turn reduce the risk of systemic bleeding. BB-10153 also has a relatively long half-life of 3-4 hours, which may also limit the potential for early reocclusion [1, 2]. METHODS: The study was a phase II, open-label, multi-center, dose escalation, single-dose administration study to determine the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of BB-10153 in ST segment elevation MI (STEMI). STEMI patients (n = 50) received a single dose of BB-10153 at one of six dose levels (1.0, 2.0, 3.0, 5.0, 7.5 and 10 mg/kg). The primary endpoint was TIMI flow grade (TFG) 3 at 60 minutes following the intravenous bolus of BB-10153. RESULTS: Mean area under the curve for drug concentration ranged from 48.0 microg.h/mL in the 1 mg/kg dose group to 788.6 microg.h/mL in the 10 mg/kg dose group. Likewise, mean Cmax generally increased with dose over the entire dose range, from 4.9 microg/mL in the 1 mg/kg dose group to 139.6 microg/mL in the 10 mg/kg dose group. The mean apparent terminal half-life (t1/2) was 4.4 hours (range 2.2 to 7.6 hours). Few patients in the 1-3 mg/kg dosage groups achieved TFG 3 on the one-hour post-dose angiogram (4/20, 20%), and no patients achieved complete ST segment resolution. The 5, 7.5 and 10 mg/kg doses were associated with similar rates of TIMI grade 3 flow of approximately three per seven patients. Pooling TFG 3 data from the 5, 7.5 and 10 mg/kg groups yielded a TIMI grade 3 flow rate of 34% (n = 10/29; range 29-43%). No patients experienced 30-day death, recurrent acute MI, cardiogenic shock, stroke or anaphylaxis during the study. One patient experienced recurrent angina and developed recurrent myocardial ischemia requiring urgent revascularization. Three patients sustained TIMI major bleeding events (one in 1 mg/kg group, two in 7.5 mg/kg group), six patients sustained TIMI minor bleeds (one in the 2, 3, 7.5 and 10 mg/kg groups, two in the 5 mg/kg group), twp patients sustained TIMI minimal bleeds (one in each of the 2 and 10 mg/kg groups) and no patients sustained intracranial hemorrhage (ICH). CONCLUSION: In a dose escalation study of a single intravenous bolus, the novel fibrinolytic agent, BB-10153 was associated with a rise in the mean area under the curve and Cmax for drug concentration over the dose range 1 to 10 mg/kg. Higher doses were associated with a range of TIMI grade 3 flow of 29-43%, and no patients experienced 30-day death, recurrent acute MI, cardiogenic shock, stroke or anaphylaxis during the study. In a dose escalation study of a single intravenous bolus, the novel fibrinolytic agent, BB-10153 was associated with a rise in the mean area under the curve and Cmax for drug concentration over the dose range 1 to 10 mg/kg. Higher doses were associated with a range of TIMI grade 3 flow of 29-43%, and no patients experienced 30-day death, recurrent acute MI, cardiogenic shock, stroke or anaphylaxis during the study.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree false
35 schema:isPartOf N5f32cdb13a5044369992352bf2a9813d
36 N6ddba2f69c8e44218466a993fa5177e3
37 sg:journal.1113719
38 schema:name Dose escalation trial of the efficacy, safety, and pharmacokinetics of a novel fibrinolytic agent, BB-10153, in patients with ST elevation MI: Results of the TIMI 31 trial
39 schema:pagination 13-21
40 schema:productId N608d28e57e974a309833450f6ca4fdd7
41 N724f303bc22e42468be1a72684994442
42 N921d7de1ef974f68817f6a0350f243d6
43 Nbe224283563741d0bb78f7439d901aab
44 Nfe0ab00cddc7499a84cd44f8938b4961
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041620834
46 https://doi.org/10.1007/s11239-006-8080-1
47 schema:sdDatePublished 2019-04-11T02:11
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher Ne471141cb8e54f0f8de823d42ba6c7c1
50 schema:url http://link.springer.com/10.1007%2Fs11239-006-8080-1
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N005476c1567a4f7e93b40a1cb06625c9 rdf:first N5caa7636777e496cb9419e6d1f731804
55 rdf:rest N4162036026874d54b0057633ea9d8005
56 N0516ebd38c464f0dbe7bbe577094b479 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
57 schema:name Humans
58 rdf:type schema:DefinedTerm
59 N0a6720f8b3df484bbf031f72b6fbb583 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Coronary Angiography
61 rdf:type schema:DefinedTerm
62 N135bc5c68dbb419fb1a991bb51a52844 rdf:first N8c4a5c7c50af494a8e308ced2bc63271
63 rdf:rest N2aad09e230f44cfd9812c41eca75674f
64 N13d1bc8932214f42a3afc90b2f49b38e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
65 schema:name Female
66 rdf:type schema:DefinedTerm
67 N13de5f41b1934bb3b92a82dc86706b98 rdf:first N70eb276b9cd044498aae7b168c62189c
68 rdf:rest N135bc5c68dbb419fb1a991bb51a52844
69 N16f368597d1d42f99b74093be15d777a schema:name Scheperziekenhuis, Emmen, Netherlands
70 rdf:type schema:Organization
71 N183d1f7cd6fb478986bd970fa6124436 rdf:first sg:person.0654626714.23
72 rdf:rest Nb0e86553087540079047c8b4c711c16e
73 N2aad09e230f44cfd9812c41eca75674f rdf:first sg:person.0667527074.47
74 rdf:rest N2d1313a31e904e9b9a8f56f283178215
75 N2d1313a31e904e9b9a8f56f283178215 rdf:first Nbc569203516e4a6688c18cb6ae8fdd3c
76 rdf:rest N005476c1567a4f7e93b40a1cb06625c9
77 N2e66a741227c40f2ad69187269ba5845 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Male
79 rdf:type schema:DefinedTerm
80 N2f95b0273406499cbc61481c92cc0b69 schema:name Cardioloog, Tweesteden Ziekenhuis, Tilberg, Netherlands
81 rdf:type schema:Organization
82 N317f0a4ac5e34d89ab504b184f5ce86c rdf:first sg:person.01351654467.89
83 rdf:rest N183d1f7cd6fb478986bd970fa6124436
84 N3bb85c01a8a44e4f9a49721d1c253d33 rdf:first sg:person.01100507210.33
85 rdf:rest N317f0a4ac5e34d89ab504b184f5ce86c
86 N4162036026874d54b0057633ea9d8005 rdf:first sg:person.0714034144.03
87 rdf:rest N6445f63eebb84da08128e838b0be04ee
88 N4ac9839457394f9bb9d84c94cc0d0c37 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Regional Blood Flow
90 rdf:type schema:DefinedTerm
91 N57f90457e416471baba14723d5dc77ac schema:name St Josephs Medical Center, Paterson, New Jersey
92 rdf:type schema:Organization
93 N5caa7636777e496cb9419e6d1f731804 schema:affiliation N2f95b0273406499cbc61481c92cc0b69
94 schema:familyName de Winter
95 schema:givenName Jobst
96 rdf:type schema:Person
97 N5e6c572dfe9c4cac88c771fca92ae683 rdf:first sg:person.01116742633.21
98 rdf:rest N94a924081313414490630b6b697176a7
99 N5f32cdb13a5044369992352bf2a9813d schema:volumeNumber 22
100 rdf:type schema:PublicationVolume
101 N608d28e57e974a309833450f6ca4fdd7 schema:name nlm_unique_id
102 schema:value 9502018
103 rdf:type schema:PropertyValue
104 N6445f63eebb84da08128e838b0be04ee rdf:first sg:person.0647744174.31
105 rdf:rest rdf:nil
106 N6a34647481ab41bb829d6357e66edb72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Dose-Response Relationship, Drug
108 rdf:type schema:DefinedTerm
109 N6ddba2f69c8e44218466a993fa5177e3 schema:issueNumber 1
110 rdf:type schema:PublicationIssue
111 N70eb276b9cd044498aae7b168c62189c schema:affiliation N820e0bfec94e412c824c53a914e5c80b
112 schema:familyName Niederman
113 schema:givenName Alan
114 rdf:type schema:Person
115 N724f303bc22e42468be1a72684994442 schema:name readcube_id
116 schema:value c6443e856a7542c8b540ecda11ecee3e91ead9794cc1006c9641323ede610c1d
117 rdf:type schema:PropertyValue
118 N73fc0e7deb844926b0bf5848b8c2ebe2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Plasminogen
120 rdf:type schema:DefinedTerm
121 N79927ac060bd49abbb4e147f9d9dd912 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Area Under Curve
123 rdf:type schema:DefinedTerm
124 N820e0bfec94e412c824c53a914e5c80b schema:name North Ridge Medical Center, Fort Lauderdale, Florida
125 rdf:type schema:Organization
126 N8331831fbd1d4eeb8ef45f87cc08c3be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Myocardial Reperfusion
128 rdf:type schema:DefinedTerm
129 N8c4a5c7c50af494a8e308ced2bc63271 schema:affiliation N16f368597d1d42f99b74093be15d777a
130 schema:familyName Westenburg
131 schema:givenName Jaap
132 rdf:type schema:Person
133 N911ebf7cbef84341910adb87f83df6a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Thrombolytic Therapy
135 rdf:type schema:DefinedTerm
136 N921d7de1ef974f68817f6a0350f243d6 schema:name doi
137 schema:value 10.1007/s11239-006-8080-1
138 rdf:type schema:PropertyValue
139 N94a924081313414490630b6b697176a7 rdf:first sg:person.01343671735.73
140 rdf:rest N9fc77bdd4ffe475cba8ab7a416fccdcf
141 N9562184b5b1b4780a7c186b275954d8b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Fibrinolytic Agents
143 rdf:type schema:DefinedTerm
144 N98b8ed5dccbe4239a7942dc9c8995bca schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Middle Aged
146 rdf:type schema:DefinedTerm
147 N9fc77bdd4ffe475cba8ab7a416fccdcf rdf:first sg:person.01203545141.80
148 rdf:rest N13de5f41b1934bb3b92a82dc86706b98
149 Nac81ac8731944e01a1859c3046ee187d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Myocardial Infarction
151 rdf:type schema:DefinedTerm
152 Nb0e86553087540079047c8b4c711c16e rdf:first sg:person.0576424350.65
153 rdf:rest N5e6c572dfe9c4cac88c771fca92ae683
154 Nbc569203516e4a6688c18cb6ae8fdd3c schema:affiliation https://www.grid.ac/institutes/grid.489081.c
155 schema:familyName Batty
156 schema:givenName John
157 rdf:type schema:Person
158 Nbe224283563741d0bb78f7439d901aab schema:name dimensions_id
159 schema:value pub.1041620834
160 rdf:type schema:PropertyValue
161 Nc46764fc33cd4c3f82aac186a551cd8c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Treatment Outcome
163 rdf:type schema:DefinedTerm
164 Nc75b1616e42f4b66b7b4778c16974e97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Injections, Intravenous
166 rdf:type schema:DefinedTerm
167 Ncd1455d8233049518d75c93a5bd534ab rdf:first sg:person.0750215673.07
168 rdf:rest N3bb85c01a8a44e4f9a49721d1c253d33
169 Ne471141cb8e54f0f8de823d42ba6c7c1 schema:name Springer Nature - SN SciGraph project
170 rdf:type schema:Organization
171 Nfe0ab00cddc7499a84cd44f8938b4961 schema:name pubmed_id
172 schema:value 16786228
173 rdf:type schema:PropertyValue
174 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
175 schema:name Medical and Health Sciences
176 rdf:type schema:DefinedTerm
177 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
178 schema:name Public Health and Health Services
179 rdf:type schema:DefinedTerm
180 sg:journal.1113719 schema:issn 0929-5305
181 1573-742X
182 schema:name Journal of Thrombosis and Thrombolysis
183 rdf:type schema:Periodical
184 sg:person.01100507210.33 schema:affiliation https://www.grid.ac/institutes/grid.414734.1
185 schema:familyName Zorkun
186 schema:givenName Cafer
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100507210.33
188 rdf:type schema:Person
189 sg:person.01116742633.21 schema:affiliation https://www.grid.ac/institutes/grid.240283.f
190 schema:familyName Mueller
191 schema:givenName Hiltrud
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116742633.21
193 rdf:type schema:Person
194 sg:person.01203545141.80 schema:affiliation https://www.grid.ac/institutes/grid.415214.7
195 schema:familyName Louwerenburg
196 schema:givenName Hans
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203545141.80
198 rdf:type schema:Person
199 sg:person.01343671735.73 schema:affiliation https://www.grid.ac/institutes/grid.416219.9
200 schema:familyName Wesdorp
201 schema:givenName Jan
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01343671735.73
203 rdf:type schema:Person
204 sg:person.01351654467.89 schema:affiliation https://www.grid.ac/institutes/grid.415214.7
205 schema:familyName Molhoek
206 schema:givenName Peter
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01351654467.89
208 rdf:type schema:Person
209 sg:person.0576424350.65 schema:affiliation https://www.grid.ac/institutes/grid.240283.f
210 schema:familyName Greenberg
211 schema:givenName Mark
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0576424350.65
213 rdf:type schema:Person
214 sg:person.0647744174.31 schema:affiliation https://www.grid.ac/institutes/grid.38142.3c
215 schema:familyName McCabe
216 schema:givenName Carolyn H.
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647744174.31
218 rdf:type schema:Person
219 sg:person.0654626714.23 schema:affiliation https://www.grid.ac/institutes/grid.414734.1
220 schema:familyName Żmudka
221 schema:givenName Krzysztof
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0654626714.23
223 rdf:type schema:Person
224 sg:person.0667527074.47 schema:affiliation N57f90457e416471baba14723d5dc77ac
225 schema:familyName Bikkina
226 schema:givenName Mahesh
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667527074.47
228 rdf:type schema:Person
229 sg:person.0714034144.03 schema:affiliation https://www.grid.ac/institutes/grid.38142.3c
230 schema:familyName Murphy
231 schema:givenName Sabina A.
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0714034144.03
233 rdf:type schema:Person
234 sg:person.0750215673.07 schema:affiliation https://www.grid.ac/institutes/grid.38142.3c
235 schema:familyName Gibson
236 schema:givenName C. Michael
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750215673.07
238 rdf:type schema:Person
239 https://app.dimensions.ai/details/publication/pub.1082701238 schema:CreativeWork
240 https://doi.org/10.1016/s0735-1097(03)00123-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037948616
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1056/nejm198504043121437 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040546057
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1111/j.1538-7836.2004.01087.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1013221463
245 rdf:type schema:CreativeWork
246 https://doi.org/10.1111/j.1538-7836.2005.01352.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1035738711
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1161/01.cir.0000013402.34759.46 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005846812
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1161/01.cir.101.2.125 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043155754
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1161/01.cir.93.5.879 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063337016
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1161/01.cir.99.21.2720 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045038090
255 rdf:type schema:CreativeWork
256 https://doi.org/10.7326/0003-4819-115-4-256 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073695908
257 rdf:type schema:CreativeWork
258 https://www.grid.ac/institutes/grid.240283.f schema:alternateName Montefiore Medical Center
259 schema:name Montefiore Medical Center, New York, New York
260 rdf:type schema:Organization
261 https://www.grid.ac/institutes/grid.38142.3c schema:alternateName Harvard University
262 schema:name TIMI Study Group, Cardiovascular Division, Brigham & Women’s Hospital and the Department of Medicine, Harvard Medical School, 350 Longwood Avenue, First Floor, 02115, Boston, MA
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.414734.1 schema:alternateName John Paul II Hospital
265 schema:name John Paul II Hospital, Krakow, Poland
266 rdf:type schema:Organization
267 https://www.grid.ac/institutes/grid.415214.7 schema:alternateName Medisch Spectrum Twente
268 schema:name Medisch Spectrum Twente, Enschede, Netherlands
269 rdf:type schema:Organization
270 https://www.grid.ac/institutes/grid.416219.9 schema:alternateName Spaarne Ziekenhuis
271 schema:name Spaarne Ziekenhuis, Heemstede, Netherlands
272 rdf:type schema:Organization
273 https://www.grid.ac/institutes/grid.489081.c schema:alternateName New Mexico Heart Institute
274 schema:name New Mexico Heart Institute, Albuquerque, New Mexico
275 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...